Bicycle Therapeutics to Present New Translational Research for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at the AACR Virtual Annual Meeting II

May 15, 2020

CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--May 15, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that new translational research for second-generation Bicycle® Toxin Conjugate (BTC) BT5528 and preclinical data for novel, fully synthetic tumor-targeted immune cell agonists (TICAs™) BT7480 and BT7455 will be presented during poster sessions at the American Association for Cancer Research (AACR) Virtual Annual Meeting II on June 22-24, 2020. All e-posters will be made available for browsing on AACR’s e-poster website starting June 22.

BT5528 is a second-generation BTC, which uses a valine-citrulline cleavable linker and a cytotoxin MMAE payload, that targets EphA2, a tumor antigen that is overexpressed in a wide range of solid tumor types and is associated with poor outcomes. BT7480 is a TICA targeting tumor antigen Nectin-4 and agonizing CD137 (4-1BB). BT7455 is a TICA targeting EphA2 and agonizing CD137.

Details on Bicycle’s poster presentations at AACR are as follows:

**Session Title:** Molecular Classification of Tumors for Diagnostics, Prognostics, and Therapeutic Outcomes 2  
**Session Category:** Experimental and Molecular Therapeutics  
**Poster Title:** A survey of EphA2 expression by immunohistochemistry (IHC) in tumor tissue microarrays (TMAs) to support BT5528 indication selection  
**Abstract #:** 3302

**Session Title:** Immunomodulatory Agents and Interventions 2  
**Session Category:** Immunology  
**Poster Title:** BT7480, a novel fully synthetic tumor-targeted immune cell agonist (TICA™) induces tumor localized 4-1BB agonism  
**Abstract #:** 5241

**Session Title:** Immunomodulatory Agents and Interventions 3  
**Session Category:** Immunology  
**Poster Title:** A fully synthetic EphA2/4-1BB tumor-targeted immune cell agonist (TICA™) induces tumor localized 4-1BB agonism  
**Abstract #:** 4613

The posters will be available on the Publications section of bicycletherapeutics.com following presentation.

About Bicycle Therapeutics

Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle®, for diseases that are underserved by existing therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive candidates for drug development. Bicycle’s lead product candidate, BT1718, a Bicycle Toxin Conjugate (BTC) that targets MT1-MMP, is being investigated in an ongoing Phase I/IIa clinical trial in collaboration with the Centre for Drug Development of Cancer Research UK. Bicycle is also evaluating BT5528, a second-generation BTC targeting EphA2, in a Company-sponsored Phase I/II study. Bicycle is headquartered in Cambridge, UK with many key functions and members of its leadership team located in Lexington, MA. For more information, visit bicycletherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200515005111/en/

Investor and Media:  
Bicycle Therapeutics  
Maren Killackey  
maren.killackey@bicycletx.com  
+1-617-203-8300

Source: Bicycle Therapeutics plc